Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (XOMAO) SEC filings page on Stock Titan is intended to organize regulatory documents related to XOMA Royalty’s preferred stock and broader capital structure. While no specific SEC filings are listed in the provided data, XOMA Royalty’s press releases describe a business model and transaction activity that are typically reflected in formal filings such as annual reports, quarterly reports, and registration statements.
XOMA Royalty characterizes itself as a biotechnology royalty aggregator that acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. When it acquires these future economic rights, the seller receives non-dilutive, non-recourse funding. The company also explains that its portfolio consists of milestone and royalty rights associated with baskets of drug products in development, and that its assets are milestone and royalty rights tied to individual drug products.
For a security like XOMAO, which represents depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock, SEC filings are the primary source for detailed terms of the preferred stock, including dividend provisions, ranking, and any redemption or liquidation preferences. In addition, XOMA Royalty’s acquisitions of companies such as HilleVax, LAVA Therapeutics, and Mural Oncology, along with royalty sharing transactions like the amended Takeda collaboration, are the types of material events that are generally described in current reports and periodic filings.
On Stock Titan, the XOMAO filings page can be used alongside XOMA Royalty’s public press releases to understand how the company reports its royalty and milestone portfolio, commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, and the impact of corporate transactions on its financial position. AI-powered summaries can help explain lengthy filings by highlighting sections that relate to preferred stock terms, royalty and milestone accounting, and the structure of acquisitions and royalty-sharing agreements.
Investors reviewing XOMAO may look to SEC documents for details on cumulative preferred dividend obligations, the relationship between the preferred stock and common equity, and disclosures about the risks and potential variability of royalty and milestone income. Combined with the company’s own explanatory notes on how it defines “portfolio” and “assets,” these filings provide a regulatory view of XOMA Royalty’s royalty aggregation strategy and the securities it has issued, including the Series B preferred stock represented by XOMAO.
XOMA Royalty Corp’s Chief Financial Officer, Jeffrey Trigilio, exercised Performance Stock Units into common shares. On April 20, 2026, 11,538 PSUs converted into 11,538 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Trigilio directly held 103,906 shares of common stock and 126,924 Performance Stock Units. Each PSU represents a contingent right to receive one share of common stock, vesting only if the stock reaches specified price targets and he continues serving the company through each vesting date.
XOMA Royalty Corp’s Chief Financial Officer, Jeffrey Trigilio, exercised Performance Stock Units into common shares. On April 20, 2026, 11,538 PSUs converted into 11,538 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Trigilio directly held 103,906 shares of common stock and 126,924 Performance Stock Units. Each PSU represents a contingent right to receive one share of common stock, vesting only if the stock reaches specified price targets and he continues serving the company through each vesting date.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, exercised performance-based equity awards into common stock. On April 20, 2026, she converted 3,370 Performance Stock Units (PSUs) into 3,370 shares of common stock at a stated price of $0.00 per share.
Following the transaction, she directly holds 41,793 common shares. The PSU award was tied to XOMA’s share price, with each PSU representing a contingent right to one share that vests only if the stock reaches specified price levels and she continues in service. After this exercise, 37,074 PSUs remain outstanding for her, scheduled to expire on March 11, 2029.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, exercised performance-based equity awards into common stock. On April 20, 2026, she converted 3,370 Performance Stock Units (PSUs) into 3,370 shares of common stock at a stated price of $0.00 per share.
Following the transaction, she directly holds 41,793 common shares. The PSU award was tied to XOMA’s share price, with each PSU representing a contingent right to one share that vests only if the stock reaches specified price levels and she continues in service. After this exercise, 37,074 PSUs remain outstanding for her, scheduled to expire on March 11, 2029.
XOMA Royalty Corp director and CEO Owen Hughes reported equity compensation activity and updated holdings. On April 20, 2026, he exercised 10,568 Performance Stock Units, receiving an equal number of shares of XOMA common stock at a stated price of $0.00 per share.
Following this transaction, he holds 191,264 shares of common stock directly and 295 shares of common stock indirectly through a 401(k) plan. He also reports 102,000 depositary shares of 8.375% Series B cumulative preferred stock and a remaining balance of 116,245 Performance Stock Units, each tied to future vesting based on stock price and continued service.
XOMA Royalty Corp director and CEO Owen Hughes reported equity compensation activity and updated holdings. On April 20, 2026, he exercised 10,568 Performance Stock Units, receiving an equal number of shares of XOMA common stock at a stated price of $0.00 per share.
Following this transaction, he holds 191,264 shares of common stock directly and 295 shares of common stock indirectly through a 401(k) plan. He also reports 102,000 depositary shares of 8.375% Series B cumulative preferred stock and a remaining balance of 116,245 Performance Stock Units, each tied to future vesting based on stock price and continued service.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.
XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.
To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.
XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.
To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.
Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.
XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.
Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.
XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.
XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.